Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389935 · ClinicalTrials.gov registry record · Phase 2
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
A Phase 2 study, sponsored by Northport Veterans Affairs Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00389935 is a Phase 2 study that has completed, run by Northport Veterans Affairs Medical Center. The registered enrollment target is 14 participants.
The verdict
NCT00389935, a Phase 2 study, has completed, sponsored by Northport Veterans Affairs Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Thalidomide is effective in the treatment of arteriovenous malformations in the gastrointestinal tract.
Interventions
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-10 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00389935
The ClinicalTrials.gov registry entry for NCT00389935 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northport Veterans Affairs Medical Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Thalidomide is the first listed.
NCT00389935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00389935 about?
NCT00389935 is a clinical study titled "Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding". The purpose of this study is to determine whether Thalidomide is effective in the treatment of arteriovenous malformations in the gastrointestinal tract.
What is the current status of trial NCT00389935?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2006-10. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00389935?
The interventions under investigation include: Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00389935?
This trial is sponsored by Northport Veterans Affairs Medical Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.